Literature DB >> 20965739

Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.

Bastian Tewes1, Bastian Frehland, Dirk Schepmann, Kai-Uwe Schmidtke, Thomas Winckler, Bernhard Wünsch.   

Abstract

NR2B selective NMDA receptor antagonists with tetrahydro-3-benzazepine-1,7-diol scaffold have been designed by formal cleavage and reconstitution of the piperidine ring of the lead compound ifenprodil (1). The secondary amine 10 represents the central building block for the synthesis of more than 25 tetrahydro-3-benzazepin-1-ols. Generally 7-hydroxy derivatives display higher NR2B receptor affinities than the corresponding 7-benzyloxy compounds. A distance of four atoms (five bond lengths) between the basic amino group and the terminal aryl moiety led to highest NR2B affinity. 3-(4-Phenylbutyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-1,7-diol (WMS-1410, 25) represents the most promising NR2B antagonist of this series showing a K(i)-value of 14nM. Compound 25 reveals excellent selectivity over more than 100 further relevant target proteins, antagonizes glutamate induced excitotoxicity (IC(50)=18.4nM) and is metabolically more stable than ifenprodil. Up to a dose of 100mg/kg 25 is well tolerated by mice and it shows dose dependent analgesic activity in the late neuropathic pain phase of the formalin assay.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20965739     DOI: 10.1016/j.bmc.2010.09.026

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Synthesis and Biological Evaluation of Novel Multi-target-Directed Benzazepines Against Excitotoxicity.

Authors:  Jatin Machhi; Navnit Prajapati; Ashutosh Tripathi; Zalak S Parikh; Ashish M Kanhed; Kirti Patel; Prakash P Pillai; Rajani Giridhar; Mange Ram Yadav
Journal:  Mol Neurobiol       Date:  2016-10-15       Impact factor: 5.590

2.  Novel GluN2B selective NMDA receptor antagonists: relative configuration of 7-meth-oxy-2-methyl-2,3,4,5-tetra-hydro-1H-3-benzazepin-1-ols.

Authors:  Bastian Tewes; Bastian Frehland; Roland Fröhlich; Bernhard Wünsch
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2016-04-15

3.  A ring expansion strategy towards diverse azaheterocycles.

Authors:  Ruirui Li; Bo Li; Hongpeng Zhang; Cheng-Wei Ju; Ying Qin; Xiao-Song Xue; Dongbing Zhao
Journal:  Nat Chem       Date:  2021-07-19       Impact factor: 24.427

4.  Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?

Authors:  Yoshihiro Shuto; Simone Thum; Louisa Temme; Dirk Schepmann; Masato Kitamura; Bernhard Wünsch
Journal:  Medchemcomm       Date:  2017-03-17       Impact factor: 3.597

5.  Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold.

Authors:  Sören Baumeister; Dirk Schepmann; Bernhard Wünsch
Journal:  Medchemcomm       Date:  2019-01-10       Impact factor: 3.597

6.  Crystal structure of (1S*,2R*)-7-benz-yloxy-2-methyl-3-tosyl-2,3,4,5-tetra-hydro-1H-3-benz-azepin-1-ol: elucidation of the relative configuration of potent allosteric GluN2B selective NMDA receptor antagonists.

Authors:  Bastian Tewes; Bastian Frehland; Roland Fröhlich; Bernhard Wünsch
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2016-04-15

7.  A common mechanism allows selective targeting of GluN2B subunit-containing N-methyl-D-aspartate receptors.

Authors:  Bernhard Wünsch; Guiscard Seebohm; Julian A Schreiber; Dirk Schepmann; Bastian Frehland; Simone Thum; Maia Datunashvili; Thomas Budde; Michael Hollmann; Nathalie Strutz-Seebohm
Journal:  Commun Biol       Date:  2019-11-15

8.  Characterization in nonhuman primates of (R)-[18F]OF-Me-NB1 and (S)-[18F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor.

Authors:  MingQiang Zheng; Hazem Ahmed; Kelly Smart; Yuping Xu; Daniel Holden; Michael Kapinos; Zachary Felchner; Ahmed Haider; Gilles Tamagnan; Richard E Carson; Yiyun Huang; Simon M Ametamey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-02       Impact factor: 10.057

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.